Wednesday, 20 Nov 2019

You are here

Effective Interferon-Free Regimen for HCV-Cryoglobulinemic Vasculitis

Rheumatologists have been challenged to treat hepatitis C virus (HCV)-induced rheumatic disease since discovery of the virus in 1989. For years, standard treatment was interferon (IFN)-based and associated with significant toxicity and a low likelihood of virologic cure (5% for IFN monotherapy to 50% with PEGylated IFN plus ribavirin).

Over the years, a series of steps have brought new and improved treatment options of HCV. After the introduction of several poorly tolerated direct acting agents, a number of new, oral, well-tolerated, IFN-free combination treatments have revolutionized the treatment of HCV with cure rates approaching 100% in just 3 months or less.

The question has been, what will these new dramatic therapies mean for the treatment of extrahepatic manifestations of HCV?

A French study published earlier this year in Annals of Rheumatic Disease evaluated the safety and efficacy of sofosbuvir 400 mg/day, a nucleotide polymerase inhibitor, plus ribavirin 200-1400 mg/day for 24 weeks to treat HCV-cryoglobulinemic vasculitis (CV), a rare yet serious complication of chronic HCV infection.

They enrolled 24 patients with active HCV-CV, excluding patients with HBV, HIV or decompensated cirrhosis. The primary endpoint was a complete clinical response of CV at week 24. Secondary endpoints included sustained virological response (SVR) at week 12, course of cryoglobulinemia, C4, ALT, the Short Form Health Questionnaire and side effects through 36 weeks of follow up.

The main clinical features of CV were purpura, peripheral neuropathy, arthralgia, glomerulonephritis and skin ulcers. 80% of patients had type II mixed cryoglobulins. Seven patients had been treated with immunosuppression for kidney disease and/or neuropathy with combinations of rituximab, IVIG and glucocorticoids. Eleven patients were naïve to antiviral treatment for HCV and 13 were previous non-responders to presumably IFN-based therapies. They found that at 12 weeks 74% experienced SVR, and 91.7% did at week 24.

A complete clinical response was seen in 21 (87.5%) of patients at week 24. Purpura, skin ulcers and arthralgia resolved in all cases, and renal disease resolved in 4 out of 5. Cryoglobulin levels disappeared in 46.1% of cases. 58% experienced any AE with the most common being fatigue, insomnia and anemia. There were 2 serious AEs.

Overall, their results are highly encouraging and contrast with previous treatment options such as first generation protease inhibitors with peg interferon and ribavirin, where SVR12 was only ~50%.

At the time this study was designed, sofosbuvir with ribavirin was the best available interferon-free regimen. Since then, many new agents have been approved but have yet to be tested in HCV-CV. For example, sofosbuvir/velpatsavir, the most recently approved combination, is a fixed-dose combo pill for genotypes 1-6, the only pan-genotypic regimen in existence, and boasts a SVR12 nearing 100% (Citation http://buff.ly/2dXsBDS). While untested in HCV-CV we would expect this combination to be even more effective and less toxic in this setting. Of course HCV-CV patients are complex and may have significant renal disease which will affect therapy options for some.

So, what is the take away here? Direct-acting agents are effective, we no longer need IFN, and this is only the tip of the iceberg. When you find patients with HCV and cryoglobulinemia, work with the hepatologist and you may cure them of HCV.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Mallinckrodt Receives SEC Subpoena

Reuters reports that Mallinckrodt Plc has received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).

ACR Responds to CY2020 Medicare Physician Fee Schedule Proposed Rule

Rheumatology leaders commend CMS for proposing E/M code changes and urge agency to make additional changes to final rule.d

Parenteral Out-Performs Oral Weekly Methotrexate

A systematic review in PLOS suggests that parenteral MTX therapy is more successful than oral MTX in achieving optimal disease activity control. 

ACR Survey Shows Half of Patients Cannot Afford Treatments

Americans living with rheumatic disease face significant healthcare challenges, according to a national patient survey released this week by the American College of Rheumatology. More than 1,500 U.S. adults living with rheumatic disease responded to the survey, which asked a range of questions related to healthcare access, affordability and lifestyle. Key findings include that even though 90 percent of respondents reported having health insurance coverage, nearly 60 percent said they had difficulty affording their medications or treatments in the past year.

Medical Use of Cannabis in 2019

JAMA has published an overview of cannabis and its medical uses. Although nearly 10% of cannabis users in the United States report using it for medicinal purposes, there is insufficient evidence to support the use of medical cannabis for most conditions for which its use is advocated or advised. Nevertheless, there is increase in favoring the public availability of cannabis, largely for the management of more than 50 medical conditions.